Myriad remains in Horizon New Jersey network, says William Blair William Blair believes there is confusion around Horizon BCBS of New Jersey's BRCA commentary, which it feels attributed to the recent pullback in shares of Myriad Genetics (MYGN). The firm said Horizon reiterated LabCorp's (LH) preferred network status and suggested that doctors should use LabCorp for BRCA testing. The insurer does not refer to a change in Myriadís network status as a participating provider in Horizonís network, the firm points out. William Blair says it has not seen evidence that Myriad is being excluded as a network provider. It maintains an Outperform rating on the stock.
LabCorp: Covance announces agreement with leading pharmaceutical company Laboratory Corporation of America Holdings announced that Covance Drug Development has received a multi-year award from a leading pharmaceutical company to use Covance's Xcellerate platform as an exclusive central monitoring solution for their worldwide clinical trials portfolio. This landmark agreement with a top-tier pharmaceutical company for Covance's first-in-kind Software-as-a-Service offering reflects the company's unique technology capabilities, and reinforces its position as an industry innovator and leader in clinical informatics solutions.